Mallinckrodt (MNK) Q4 results: Revenues: $804.9M (-3.6%); Acthar Gel: $232.6M (-17.8%); INOmax: $143.8M (+3.7%); Ofirmev: $111.8M (+28.2%). Net loss: ($1,161M) (+68.8%); loss/share: ($13.80) (+69.1%); non-GAAP Net Income: $202.1M (+9.4%); non-GAAP EPS: $2.40 (+10.1%). CF Ops: $742.9M (+11.6%). Shares are up 19% premarket. Previously: Mallinckrodt EPS beats by $0.35, bea